SpringWorks Therapeutics, Inc. acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is nirogacestat, an oral small molecule gamma secretase inhibitor that is in Phase III clinical trial for the treatment of desmoid tumors. The company is also developing mirdametinib, an oral small molecule MEK inhibitor that is in Phase 2b clinical trials for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas, as well as Phase 1/2a clinical trial for the treatment of NF1-PN; mirdametinib + lifirafenib, a combination therapy that is in Phase 1b/2 clinical trial in patients with advanced or refractory solid tumors; and mirdametinib in monotherapy and combination approaches to treat solid tumors. In addition, it develops BGB-3245, an oral selective small molecule inhibitor of monomeric and dimeric forms of activating BRAF mutations, which is in Phase I clinical trial. The company has collaborations with BeiGene, Ltd., GlaxoSmithKline LLC, and Allogene to develop combination approaches with nirogacestat and mirdametinib; and license agreements with Pfizer Inc. for nirogacestat and mirdametinib. It also has a license agreement with Katholieke Universiteit Leuven and the Flanders Institute for Biotechnology for a portfolio of novel small molecule inhibitors of the TEA Domain; and Dana-Farber Cancer Institute for a portfolio of novel small molecule inhibitors of Epidermal Growth Factor Receptor. In addition, the company has clinical collaboration agreement with Janssen Biotech, Inc., Precision BioSciences, Inc., Seagen Inc., and AbbVie, Inc. SpringWorks Therapeutics, Inc. was founded in 2017 and is headquartered in Stamford, Connecticut.

SpringWorks Therapeutics, Inc.

SpringWorks Therapeutics is focused on developing targeted oncology treatments for rare diseases and cancer.

Metric
Company Name	SpringWorks Therapeutics, Inc.
Symbol	SWTX
MSH ID	COM:SPRINGWORKSTX
Market	STOCKS
Sector	Healthcare
Industry	Biotechnology
Country	US
Stage
Employee Count	305
Website	springworkstx.com
LinkedIn
Founders

Metric
Market Cap	2.93B
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue	5.45M
Revenue (LTM)
Revenue (NTM)
Gross Profit	5.03M
EBITDA	-341.35M
Operating Income	-343.01M
Net Income	-325.10M
EPS	-0.01
Diluted EPS	-0.01
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.92
Operating Profit Margin	-3.50
EBITDA Margin	-62.67
Net Profit Margin	-3.28
Return on Equity	-0.56
Return on Assets	-0.44
Return on Capital Employed	-0.53

COM:SPRINGWORKSTX

SpringWorks Therapeutics

Last Close

36.30

22/11 21:00

Market Cap

2.93B

Beta: -

Volume Today

1.41M

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	-10.18
P/B Ratio	7.64
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	170.69
EV Multiple	-7.10

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding	484.68
Operating Cycle	634.37
Cash Conversion Cycle	88.69
Asset Turnover	0.15

Metric
Operating Cash Flow	-222.79M
Free Cash Flow	-230.18M
Cash Flow to Debt	-31.57
Operating Cash Flow/Sales	-2.55
Free Cash Flow Yield	-0.06

Metric
Cash & Equivalents	176.05M
Accounts Receivable	-5.93M
Inventory	3.10M
Goodwill
Debt to Capitalization	0.01
Debt to Assets	0.02
Current Ratio	8.60
Quick Ratio	7.77

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	3.88
R&D to Revenue	6.36
SG&A to Revenue	7.83